Mostrar el registro sencillo

dc.contributor.authorMartínez Campa, Carlos Manuel es_ES
dc.contributor.authorAlonso González, Carolina es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-12-02T16:41:17Z
dc.date.available2022-12-02T16:41:17Z
dc.date.issued2020es_ES
dc.identifier.issn1661-6596es_ES
dc.identifier.issn1422-0067es_ES
dc.identifier.otherSAF2016-77103-Pes_ES
dc.identifier.urihttps://hdl.handle.net/10902/26825
dc.description.abstractThe Special Issue entitled "New Strategies in Cancer Pharmacotherapy: Development of Hormonal Antineoplastic Drugs, Cytotoxic Drugs and Targeted Therapies" was conceived with the idea of compiling information on the latest advances in the treatment of both hormone-dependent and hormone-independent cancers [...].es_ES
dc.description.sponsorshipThe present study was funded by grants from the Spanish Economy and Competitiveness Ministry (SAF2016-77103-P) and from Instituto de Investigación Sanitaria Valdecilla (NVAL 16/01).es_ES
dc.format.extent4 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution 4.0 International*
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInt J Mol Sci . 2020 Jun 8;21(11):4081es_ES
dc.titleEditorial for the special issue “new strategies in cancer pharmacotherapy: Development of hormonal antineoplastic drugs, cytotoxic drugs and targeted therapies”es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://www.doi.org/10.3390/ijms21114081es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/ijms21114081es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International